Hypercalcemia in intermediate grade non-Hodgkin's lymphoma (NHL) (Meeting abstract).

Important note: Information in this article was accurate in 1994. The state of the art may have changed since the publication date.

Hypercalcemia in intermediate grade non-Hodgkin's lymphoma (NHL) (Meeting abstract).

Proc Annu Meet Am Soc Clin Oncol; 13:A1285 1994. Unique Identifier : AIDSLINE ICDB/94601281
Jendiroba DB; Seymour JF; Swan F; Cabanillas F; UT MD Anderson Cancer Center, Houston, TX 77030

Abstract: The incidence, features and prognostic significance of hypercalcemia complicating NHL have not been determined. We analyzed 183 consecutive patients (pts) with untreated intermediate-grade NHL treated on protocol between 1988 and 1992. Hypercalcemia was defined as a corrected serum calcium (CCa) of greater than 10 mg/dl where CCa = total calcium + 0.8[4.0 - albumin]. All pts were HIV seronegative and classified into favorable (n=44) or unfavorable (n=139) groups according to published criteria (Blood 74:551, 1989). Hypercalcemia (median CCa 10.4, range 10.1-14.2) was more common among unfavorable pts (2% vs 19%, p=0.007). Limiting all further analyses to the unfavorable pts, there was no difference (p greater than 0.2) between those with high or normal CCa, respectively, in the incidence of T-cell phenotype (8% vs 6%) or bone lesions (both 12%). Adverse features were more common in pts with a high CCa: International Index greater than or equal to 3 (62% vs 35%, p=0.02), high LDH (88% vs 54%, p=0.005), beta2-microglobulin greater than or equal to 3 mg/l (64% vs 31%, p=0.002), PS greater than or equal to 2 (38% vs 15%, p=0.007). Despite identical therapy, pts with high CCa had shorter progression free (PFS) (p less than 0.01) and overall (OS) (p=0.01) survival. At 3 yr PFS was 57% vs 34% and OS 68% vs 38%, respectively. A high CCa at diagnosis was not always associated with a high CCa at relapse (18% vs 10%). Hypercalcemia in NHL is not isolated to pts with T-cell disease or bone lesions. A high CCa is a powerful adverse feature, possibly due to its association with other adverse indicators.

Keywords: Calcium/BLOOD Human Hypercalcemia/*BLOOD/MORTALITY Lymphoma, Intermediate-Grade/*BLOOD/MORTALITY Paraneoplastic Syndromes/*BLOOD/MORTALITY Prognosis Survival Rate ABSTRACT

940930
M9491047

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1994. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1994. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .